Pemvidutide vs Retatrutide
How Pemvidutide and Retatrutide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Pemvidutide and Retatrutide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Pemvidutide vs Retatrutide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Pemvidutide | Retatrutide |
|---|---|---|
| What it is | Synthetic peptide dual agonist of the GLP-1 and glucagon receptors | Synthetic triple-agonist peptide (one molecule that switches on the GIP, GLP-1, and glucagon receptors) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Mixed | Human RCT · Helped |
| Studied / approved for | Metabolic dysfunction-associated steatohepatitis (MASH); Obesity; Alcohol use disorder; Alcohol-associated liver disease | Obesity / weight loss; Type 2 diabetes; MASLD (fatty liver disease); Obesity-related cardiovascular & kidney outcomes; Knee osteoarthritis pain in people with obesity or overweight; Obstructive sleep apnea in people with obesity |
| US regulatory status (2026) | investigational (as of Jul 2026) | investigational (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 33 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Human randomized trials provide a useful short-term safety picture, with gastrointestinal effects such as nausea, vomiting, diarrhea and constipation most prominent. IMPACT reported few discontinuations due to adverse events through 24 weeks, but Phase 2 trials cannot establish the safety of longer or wider use. Pemvidutide remains investigational. | Retatrutide has more human safety data than most compounds on this site, because it has reported phase 3 trials — but it is still investigational and its long-term profile is being filled in during ongoing phase 3 studies. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related and usually heaviest early on. Like other incretin drugs, it carries a rodent thyroid C-cell tumor signal whose human relevance is unsettled, and it raises heart rate in a dose-dependent way. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.